ESMO Sarcoma and Rare Cancers Congress 2024
![Sarcoma&Rare_Neuroendocrine_Panelists](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-sarcoma-rare-cancers-2024/coverage/sarcoma-rare_neuroendocrine_panelists/18923040-1-eng-GB/sarcoma-rare_neuroendocrine_panelists_i770.jpg)
A new combination treatment shows early promise in GEP-NECs
Lurbinectedin and irinotecan demonstrate a synergic clinical effect in patients with neuroendocrine carcinomas of gastroenteropatic primary site after chemotherapy failure
![Sarcoma&Rare_PP1](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-sarcoma-rare-cancers-2024/coverage/sarcoma-rare_pp1/18914205-1-eng-GB/sarcoma-rare_pp1_i770.jpg)
Can sarcomas benefit from targeted treatments active in other tumour types?
Two studies in sarcoma explore the promise of ADCs and theranostics realised in different tumours.
![Sarcoma&Rare_Cesar_Serrano](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-sarcoma-rare-cancers-2024/coverage/sarcoma-rare_cesar_serrano/18914109-3-eng-GB/sarcoma-rare_cesar_serrano_i770.jpg)
New hope for MDM2 inhibition in liposarcomas?
An early-phase trial shows the efficacy of brigimadlin in dedifferentiated and well-differentiated liposarcomas, but confirmation from phase III results is still awaited
![Sarcoma&Rare_Silvia_Stacchiotti](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-sarcoma-rare-cancers-2024/coverage/sarcoma-rare_silvia_stacchiotti/18922818-1-eng-GB/sarcoma-rare_silvia_stacchiotti_i770.jpg)
Desmoid tumours: nirogacestat improves quality of life also in stable disease
In a post hoc analysis of the DeFi trial, a reduction in symptom burden was reported, with benefits occurring early in treated patients
![Editorial_Rare](/var/esmo/storage/images/media/esmo-daily-reporter/images/editorials/editorial_rare/18909833-1-eng-GB/editorial_rare_i770.jpg)
Should rare cancers still be (in) a niche of oncology?
ESMO is sustaining its efforts to give rare cancers a more prominent place in oncology
![Claudia Valverde](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/claudia-valverde/18910090-1-eng-GB/claudia-valverde_i770.jpg)
Centralisation of care in rare cancers – what are the next steps?
Innovative models and increased cross-border collaborations can further support the implementation of rare cancer reference centres to expedite diagnosis and improve treatment
![Sarcoma&Rare_Delegates_Venue_01](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-sarcoma-rare-cancers-2024/coverage/sarcoma-rare_delegates_venue_01/18909827-1-eng-GB/sarcoma-rare_delegates_venue_01_i770.jpg)
Studies provide further evidence to support continued imatinib in two different GIST indications
Uninterrupted imatinib is essential to optimise outcomes in metastatic and high-risk resected GIST